Loading...
Market
Number of additional generic GLP-1 drugs approved by FDA by June 30, 2025
4
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
FDA approval announcements and database
Story
Teva Launches First Generic GLP-1 Drug, Liraglutide (Victoza)
Jun 26, 2024, 10:01 AM
On June 24, 2024, Teva launched the first generic version of Novo Nordisk's GLP-1 receptor agonist drug, liraglutide, known commercially as Victoza. This generic introduction marks a significant milestone in the diabetes and obesity medication market. The higher dose of 3mg daily, which is used for obesity, could potentially make the treatment more accessible to those in need. However, experts are cautious about immediate price reductions, citing market inertia and other factors.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
No reduction • 33%
Up to 25% reduction • 33%
More than 25% reduction • 33%
Zepbound • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%